Skip to content
Biotechnology, Medical Health Aged Care

$27 million to map 50 million human cells and uncover genetic fingerprints of disease

Illumina/Garvan Institute 5 mins read

Sydney, Australia, Wednesday, 1 May 2024 - Illumina, Inc. (NASDAQ: ILMN)

Embargo and media call: 10 am, Garvan Institute, 384 Victoria St, Darlinghurst NSW

With researchers, The Hon. David Harris MP, NSW Minister for Medical Research,

and Madeleine Jandura who was diagnosed with ulcerative colitis at age 11.

Illumina, a global genomics and human health company, has partnered with the Garvan Institute of Medical Research’s TenK10K project to help transform the treatment of complex diseases, starting with autoimmune diseases, with a joint investment of $27 million AUD.

The Garvan Institute plans to map 50 million human cells from 10,000 people to identify unique genomic fingerprints of autoimmune diseases, heart diseases and cancer, building on the early success of a clinical trial for Crohn’s disease.

Crohn’s disease affects more than 80,000 Australians. As with many autoimmune diseases, predicting which treatments will work best for which patients is currently impossible. The OneK1K clinical trial across 10 Sydney hospitals shows that a genetic fingerprint project led by the Garvan Institute can help match individual patients with the most effective treatment.

Illumina is supporting the project with supplies, equipment and specialist research support, which will provide a critical boost for Garvan’s single-cell and whole genome sequencing research and enable upscaling to make the TenK10K project the largest project of its kind. The investment will enable the Garvan Institute to improve how accurately disease-linked immune cell fingerprints can be identified and develop:

  • Commercial tests to identify the right therapy for challenging autoimmune diseases including multiple sclerosis, rheumatoid arthritis, lupus, type 1 diabetes, spondylitis, inflammatory bowel disease, and Crohn’s disease
  • Early trials of powerful new RNA therapies
  • Potential early targets for treatments for cancers and long COVID
  • Tests to track the aftermath of heart attacks and identify risk of sudden death.

“This work has the potential to enable a significant step forward in personalised medicine. In 2022, in a paper in Science, we announced that we had analysed the genomic profile of more than one million cells from 1,000 people to identify markers of autoimmune disease,” says Professor Joseph Powell, leader of the OneK1K and now TenK10K project at the Garvan Institute of Medical Research. “We were able to do this using single-cell sequencing, a new technology that allows us to detect subtle changes in individual cells,” he says.

“That led to a proof-of-principle clinical trial at 10 Sydney hospitals to see if we can improve the treatment of Crohn’s disease. The early results suggest we can predict a patient’s response to a therapy based on their genetic profile. Through single-cell sequencing, which analyses individual cells rather than an average of many cells, we can see fingerprints that we’ve never been able to distinguish before.”

“Now, with the help of Illumina, TenK10K will build on this work to generate single-cell data on around 50 million cells from 10,000 individuals to further improve the accuracy of predicting disease risk and treatment response. This research will help identify the subtle genomic differences in everyone’s cells, which will help us speed up diagnosis and treatment for many diseases. We are excited by translational opportunities that come from combining this globally leading biotechnology resource with advanced machine learning methods,” says Professor Powell.

NSW Minister for Medical Research David Harris congratulated Garvan Institute of Medical Research and Illumina on this unique partnership.

“This partnership will help advance the field of genomics and personalised medicine, delivering benefits to patients across NSW,” Mr Harris said.

“The future of this work will allow for next-generation sequencing of patients’ genomic data to ensure they receive more personalised treatment for chronic and autoimmune conditions.

“NSW has a strong history of investing in ground-breaking genomic research. New collaborative partnerships such as these are vital to ensure NSW continues to be a world leader in delivering cutting-edge and truly translational research that will help meet the challenges and needs of future health care delivery.”

“In 2007 at age 11 I was diagnosed with ulcerative colitis,” says Madeleine Jandura.

“Over the next twelve years I had to deal with countless doctors and specialist visits, blood tests, scans, colonoscopies, emergency visits, long hospital stays, and countless ever changing oral and intravenous medications. After exhausting all options with medications, I spent the next five years undergoing four major surgeries.”

“Now I am finally rid of this disease, though I will have to deal with the impacts of it for the rest of my life and the possibility it may return.”

“I am excited to hear now how Joseph and his team are working to get faster answers and faster treatments,” she says.

Professor Benjamin Kile, Executive Director of the Garvan Institute says: “This partnership is a testament to the world-leading research happening at Garvan, leveraging our unique expertise across clinical and research fronts. This innovative research is set to transform patient care for some of the most difficult-to-treat diseases.”

“A few years ago, this project would have been impossible,” says Illumina’s Simon Giuliano, commercial lead for Oceania. “Now we have the technology to rapidly and cheaply detect the difference in the genomics of individual cells using next-generation sequencing. And that opens up the potential of a new era of personalised health, where the variation in every human cell flags the right treatment for an individual’s disease, avoiding the trial and error in the past.”

 

 


About us:

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.

Illumina has installed more than 380 sequencers in Australia and works closely with partners in Australia such as the Garvan Institute, Omico Australia, Minderoo Foundation, University of Melbourne, Peter MacCallum Cancer Centre and Australian Genome Research Facility (AGRF).

Visit illumina.com and connect on X (Twitter), Facebook, LinkedIn, Instagram, TikTok, and YouTube.

About the Garvan Institute of Medical Research

The Garvan Institute of Medical Research brings together world-leading researchers and clinicians, collaborating locally and globally, to improve human health. Our mission is to harness all the information encoded in our genome to better diagnose, treat, predict and prevent disease. From the individual patient with rare disease, to the many thousands affected by complex illnesses, we are pioneering discoveries across diseases that have the deepest impact on our community.

About next-generation sequencing

Next-generation sequencing (NGS) is a massively parallel sequencing technology that offers ultra-high throughput, scalability, and speed. The technology is used to determine the order of nucleotides in entire genomes or targeted regions of DNA or RNA. NGS has revolutionised the biological sciences, allowing labs to perform a wide variety of applications and study biological systems at a level never before possible.

Today's complex genomics questions demand a depth of information beyond the capacity of traditional DNA sequencing technologies. NGS has filled that gap and become an everyday tool to address these questions. https://sapac.illumina.com/science/technology/next-generation-sequencing.html#:~:text=What%20is%20NGS%3F,regions%20of%20DNA%20or%20RNA.

About OneK1K and TenK10K

OneK1K is a study demonstrating how genetics contribute to the risk of immune disease at a cellular level. Using the ground-breaking technology of the Garvan-Weizmann Centre for Cellular Genomics, the study aims to identify and prioritise new drug targets for specific cell types in individual patients and will have an impact on three main areas: autoimmunity, immuno-oncology and haematology disease.

This research was supported by National Health and Medical Research Council Research Fellowship, Practitioner Fellowship, Career Development Fellowship and Investigator Fellowship; The Alex Gadomski Fellowship, funded by Maddie Riewoldt’s Vision. Additional grant support was provided by the National Health and Medical Research Council, the Australian Research Council and the Royal Hobart Hospital Research Foundation.

OneK1K analysed the genomic profile of more than one million cells from 1,000 people. With the support of Illumina, TenK10K will analyse 50 million cells from 10,000 individuals.

Professor Powell is Director of the Translational Genomics Program at the Garvan Institute and the Director of the Cellular Genomics Futures Institute at UNSW Sydney.


Contact details:

Niall Byrne, Science in Public for Illumina, niall@scienceinpublic.com.au, 0417-131-977
Dr Viviane Richter, Garvan Institute, v.richter@garvan.org.au, 0404-999-682
Tanya Ha, Science in Public for Illumina, tanya@scienceinpublic.com.au, 0404-083-863

More from this category

  • Medical Health Aged Care
  • 30/05/2024
  • 22:22
Rhea

Rhea Launches with Senior Advisory Panel, Growth Acquisitions and Strategic Partnerships to Advance Fertility Journeys for the Modern Family

Launch coincides with follow-on funding round led by Thiel Capital to expand global footprint SINGAPORE–BUSINESS WIRE– Rhea, a global reproductive health services company focused…

  • Contains:
  • Biotechnology
  • 30/05/2024
  • 20:07
Moolec Science SA

Moolec Science Presents Third Quarter Fiscal Year 2024 Business Update

LUXEMBOURG / ACCESSWIRE / May 30, 2024 / Moolec Science SA (NASDAQ:MLEC) a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming technology, announced today its Business Update for the third quarter of Fiscal Year 2024 ended March 31, 2024.Moolec Science Logo The main highlights of Moolec's business update are as follows:Piggy Sooy™ Product | Soybean Platform: Moolec's patented soybean product received USDA-APHIS Regulatory Status Review approval in April 2024.Safflower Platform: GLASO™ planting campaign progressing as expected. Two US Patents granted for production of chymosin in safflower seeds (SPC2) extended exclusive technology protection until 2041.Financial…

  • Medical Health Aged Care
  • 30/05/2024
  • 11:53
Royal Australian College of GPs

RACGP backs politicians calls for onsite GP at Parliament

Australia’s peak GPbody has expressed disappointment that funding has not been provided for an onsite GP at Parliament despite recommendations in the Jenkins report and agitation from Senators and members of parliament. The Department of Parliamentary Services secretary told Senate Estimates funding for an onsite GP wasn’t sought in the most recent Federal Budget. The Royal Australian College of GPs (RACGP) Vice President Associate Professor Michael Clements backed calls for an onsite GP to improve the health and wellbeing of people working there. “Everyone deserves the quality care your get from a GP who knows you and your history, including…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.